Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) included InnoCare's ICP‑B794 and Hiteck Biological's Aponermin in the "Care Program – Extension" pilot project, while Genhouse…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

NMPA Approves Expanded Indication for Merck's Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China
CompanyDrug

NMPA Approves Expanded Indication for Merck’s Winrevair (Sotatercept) – First‑in‑Class Activin Signaling Inhibitor Now Covers WHO Functional Class II–IV PAH in China

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation
CompanyDrug

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Leads Biolabs' LBL-024 Granted Orphan Drug Designation by Japan's MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma
CompanyDrug

Leads Biolabs’ LBL-024 Granted Orphan Drug Designation by Japan’s MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Shanghai RAAS Blood Products Co., Ltd. (SHE: 002252) announced its intention to acquire a 100% equity stake in Boehringer Ingelheim (China) Investment Co., Ltd. in an all‑cash transaction with a value expected not to exceed RMB 20 million, a move…

HitGen Co‑Invests in Connexus Therapeutics' Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

HitGen Co‑Invests in Connexus Therapeutics’ Series A – OrbiMed‑Backed Oncology Startup Founded on Phased Technology Licensing

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery
CompanyDeals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings
CompanyDeals

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer's Gene Therapy SP-201 Enter Next Development Phase
CompanyDeals

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer’s Gene Therapy SP-201 Enter Next Development Phase

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology
CompanyDeals

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

InnoCare Pharma Limited (HKG: 9969; SHA: 688428) announced that it has entered into a strategic research, development, and licensing agreement with Eli Lilly and Company (NYSE: LLY) to develop innovative…

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs
CompanyDeals

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency
CompanyDeals

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform
CompanyDeals

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

- Advertisement -
Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status
CompanyDeals

Qiantang Longyue Closes Over RMB 100 Million A++ Round Led by Huimei Capital – Drug Delivery Systems Platform Nears Unicorn Status

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

More News

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%
Company

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis
CompanyDrug

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION
CompanyDrug

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC
CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline
Company

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Show More